Yasir Y. Elamin

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone, William N. William, Annikka Weissferdt et al. · Nature Medicine · 2021 · 604 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

Yanshuo Chu, Enyu Dai, Yating Li et al. · Nature Medicine · 2023 · 485 citations · Full text

Medicine, Cancer Biology, Oncology +14

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan et al. · Nature Medicine · 2018 · 455 citations

Medicine, Oncology, Pharmacology +14

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R. S. K. Vijayan et al. · Nature · 2021 · 452 citations · Full text

Medicine, Molecular Genetics, Oncology +14